Literature DB >> 10967118

Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3).

H R Lijnen1, B Arza, B Van Hoef, D Collen, P J Declerck.   

Abstract

Matrix metalloproteinase-3 (MMP-3 or stromelysin-1) specifically hydrolyzes the Ser(337)-Ser(338) (P10-P9) and Val(341)-Ile(342) (P6-P5) peptide bonds in human plasminogen activator inhibitor-1 (PAI-1). Cleavage is completely abolished in the presence of the metal chelators EDTA or 1,10-phenanthroline. A stabilized active PAI-1 variant was also cleaved by MMP-3. At an enzyme/substrate ratio of 1/10 at 37 degrees C, PAI-1 protein cleavage occurred with half-lives of 27 or 14 min for active or stable PAI-1 and was associated with rapid loss of inhibitory activity toward tissue-type plasminogen activator with half-lives of 15 or 13 min, respectively. A substrate-like variant of PAI-1, lacking inhibitory activity but with exposed reactive site loop, was cleaved with a half-life of 23 min, whereas latent PAI-1 in which a major part of the reactive site loop is inserted into the molecule, was resistant to cleavage. Biospecific interaction analysis indicated comparable binding of active, stable, and substrate PAI-1 to both proMMP-3 and MMP-3 (K(A) of 12-22 x 10(6) m(-1)), whereas binding of latent PAI-1 occurred with lower affinity (1.7-2.3 x 10(6) m(-1)). Stable PAI-1 bound to vitronectin was cleaved and inactivated by MMP-3 in a manner comparable with that of free PAI-1; however, the cleaved protein did not bind to vitronectin. Cleavage and inactivation of PAI-1 by MMP-3 may thus constitute a mechanism decreasing the antiproteolytic activity of PAI-1 and impairing the potential inhibitory effect of vitronectin-bound PAI-1 on cell adhesion and/or migration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10967118     DOI: 10.1074/jbc.M006475200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Enhanced fibrinolysis in fingerstick blood samples: a possible role for matrix metalloproteinase-9.

Authors:  Rachna Vanjani; Melissa Park; Brittany Holt; Ann Cullinane; Paula Merryman; McDonald Horne
Journal:  Thromb Res       Date:  2007-04-03       Impact factor: 3.944

2.  The conversion of active to latent plasminogen activator inhibitor-1 is an energetically silent event.

Authors:  Christian Boudier; Ann Gils; Paul J Declerck; Joseph G Bieth
Journal:  Biophys J       Date:  2005-01-14       Impact factor: 4.033

3.  Hyperglycemia-suppressed expression of Serpine1 contributes to delayed epithelial wound healing in diabetic mouse corneas.

Authors:  Haijing Sun; Xiaofan Mi; Nan Gao; Chenxi Yan; Fu-Shin Yu
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-05       Impact factor: 4.799

4.  Matrix metalloproteinase-3 (MMP3) and MMP9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke.

Authors:  Robert C Kaplan; Nicholas L Smith; Stanley Zucker; Susan R Heckbert; Kenneth Rice; Bruce M Psaty
Journal:  Atherosclerosis       Date:  2008-03-14       Impact factor: 5.162

5.  NF-kappaB and ZBP-89 regulate MMP-3 expression via a polymorphic site in the promoter.

Authors:  Ruth C Borghaei; Grzegorz Gorski; Masoud Javadi
Journal:  Biochem Biophys Res Commun       Date:  2009-03-09       Impact factor: 3.575

Review 6.  MMP induction and inhibition in myocardial infarction.

Authors:  Merry L Lindsey
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

7.  IL-4 inhibition of IL-1 induced Matrix metalloproteinase-3 (MMP-3) expression in human fibroblasts involves decreased AP-1 activation via negative crosstalk involving of Jun N-terminal kinase (JNK).

Authors:  Mariah Chambers; Garrett Kirkpatrick; Michel Evans; Grzegorz Gorski; Sara Foster; Ruth C Borghaei
Journal:  Exp Cell Res       Date:  2013-04-19       Impact factor: 3.905

8.  Human retinal pigment epithelial lysis of extracellular matrix: functional urokinase plasminogen activator receptor, collagenase, and elastase.

Authors:  Susan G Elner
Journal:  Trans Am Ophthalmol Soc       Date:  2002

9.  The antiangiogenic activity of rPAI-1(23) inhibits vasa vasorum and growth of atherosclerotic plaque.

Authors:  Mary Drinane; Jessica Mollmark; Lyubomir Zagorchev; Karen Moodie; Baiming Sun; Amy Hall; Samantha Shipman; Peter Morganelli; Michael Simons; Mary Jo Mulligan-Kehoe
Journal:  Circ Res       Date:  2009-01-02       Impact factor: 17.367

10.  Interleukin-4 suppresses IL-1-induced expression of matrix metalloproteinase-3 in human gingival fibroblasts.

Authors:  Kosunique Jenkins; Masoud Javadi; Ruth Carter Borghaei
Journal:  J Periodontol       Date:  2004-02       Impact factor: 6.993

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.